The lancet. Diabetes & endocrinology
-
Lancet Diabetes Endocrinol · Mar 2015
Randomized Controlled Trial Multicenter StudyRenal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial.
-
Lancet Diabetes Endocrinol · Mar 2015
Randomized Controlled Trial Comparative StudyOnce-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study.
Trelagliptin is a novel once-weekly oral DPP-4 inhibitor. We assessed the efficacy and safety of trelagliptin versus the daily oral DPP-4 inhibitor alogliptin in Japanese patients with type 2 diabetes. ⋯ Takeda Pharmaceutical Company.
-
Lancet Diabetes Endocrinol · Mar 2015
Review Meta Analysis Historical ArticleRisk of all-cause mortality and vascular events in women versus men with type 1 diabetes: a systematic review and meta-analysis.
Studies have suggested sex differences in the mortality rate associated with type 1 diabetes. We did a meta-analysis to provide reliable estimates of any sex differences in the effect of type 1 diabetes on risk of all-cause mortality and cause-specific outcomes. ⋯ None.